Top Markets
#1 Nesa Nesa +619.32%
#2 Black Phoenix Black Phoenix +194.46%
#3 MetaDAO MetaDAO +30.73%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +22.27%
#5 Ontology Gas Ontology Gas +19.38%
#6 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +18.21%
#7 Bedrock Bedrock +17.90%
#8 Stacks Stacks +17.69%
#9 Purr Purr +15.60%
#10 Helium Helium +14.45%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990
Rank in Stocks #1496
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company,... Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Share Price
$66.27
Market Cap
$15.45B
Change (1 day)
-0.96%
Change (1 year)
10.19%
Country
CN
Trade Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)

Category

Healthcare
Number of shares outstanding for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Number of shares outstanding as of August 2026: 0
According to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH